<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144613">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218074</url>
  </required_header>
  <id_info>
    <org_study_id>00-04</org_study_id>
    <nct_id>NCT01218074</nct_id>
  </id_info>
  <brief_title>Platelets Antiaggregation Control Enhancement (PACE) Study</brief_title>
  <acronym>PACE</acronym>
  <official_title>Platelets Antiaggregation Control Enhancement Study: an Independent Randomized Blind Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiochirurgia E.H.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiochirurgia E.H.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many patients undergo cardiac surgery without proper suspension of antiaggregation drugs.
      This is blamed to increase dramatically bleeding and use of allogenic blood transfusions.
      The investigators test the hypothesis that routine use of aggregometry could show
      antiaggregated patient and lead to normalization of platelet function via administration of
      Desmopressin thus limiting bleeding and transfusions.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding Volume</measure>
    <time_frame>12 hours after end of operation</time_frame>
    <description>Total amount of bleeding in the first 12 hours after cardiac surgery expressed as milliliters of blood in the chest drains reservoir.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use of allogenic blood transfusions.</measure>
    <time_frame>In hospital stay (usually 5 to 8 days after operation)</time_frame>
    <description>Number of allogenic blood units transfused per patients during the full hospital stay, usually 5 to 8 days after operation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Bleeding</condition>
  <condition>Blood Transfusion</condition>
  <arm_group>
    <arm_group_label>Thromboelastography alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo standard of care Thromboelastography to evaluate overall coagulation performances.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aggregometry+Tromboelastography</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aggregometry+Thromboelastography</intervention_name>
    <description>Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.</description>
    <arm_group_label>Aggregometry+Tromboelastography</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thromboelastography Alone</intervention_name>
    <description>Patients undergo standard of care Thromboelastography to evaluate overall coagulation performance.</description>
    <arm_group_label>Thromboelastography alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients undergoing surgical myocardial revascularization.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luca P Weltert, MD</last_name>
    <phone>+393478880617</phone>
    <email>lweltert@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saverio Nardella, MD</last_name>
    <email>save78@virgilio.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>European Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca P Weltert, MD</last_name>
      <phone>+393478880617</phone>
      <email>lweltert@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Saverio Nardella, MD</last_name>
      <email>save78@virgilio.it</email>
    </contact_backup>
    <investigator>
      <last_name>Luca P Weltert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 13, 2013</lastchanged_date>
  <firstreceived_date>October 5, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardiochirurgia E.H.</investigator_affiliation>
    <investigator_full_name>Luca Weltert</investigator_full_name>
    <investigator_title>Project Leader Luca Weltert</investigator_title>
  </responsible_party>
  <keyword>bleeding</keyword>
  <keyword>blood sparing procedure</keyword>
  <keyword>desmopressin</keyword>
  <keyword>aggregometry</keyword>
  <keyword>thromboelastography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
